TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05368740

Intervention type: DEVICE
Intervention: integrated pulmonary index monitor
Description: Integrated Pulmonary Index (IPI) is a new monitoring method calculated using respiratory rate (RR), end-tidal carbon dioxide (EtCO2), peripheral oxygen saturation (SpO2), and heart rate (HR). It is designed to obtain information about the patients' oxygenation and ventilation in the form of a single value or waveform from 1 to 10 with a mathematical algorithm using fuzzy logic. According to this scoring system; 10= normal, 8-9= within normal range, 7= close to normal range, requires attention, 5-6= requires attention and may require intervention, 3-4= requires intervention, 1-2= requires immediate intervention \[2\].
Study: NCT03471442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anesthetics, Local
Description: Weight-based dosing of this local anesthetic mixture.
Study: NCT04424927

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRV-015
Description: Fully human monoclonal antibody against interleukin 15 (IL-15)
Study: NCT03471442

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anesthetics, Local
Description: Weight-based dosing of this local anesthetic mixture.
Study: NCT00749944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varenicline
Description: 1 mg tablets twice daily by mouth (after one week of uptitration: 0.5mg once daily for three days, 0.5mg twice daily for four days)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 mg tablets twice daily by mouth (after one week of uptitration: 0.5mg once daily for three days, 0.5mg twice daily for four days)
Study: NCT04424927

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRV-015
Description: Fully human monoclonal antibody against interleukin 15 (IL-15)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRV-015
Description: Fully human monoclonal antibody against interleukin 15 (IL-15)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01107223

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Training to antibiotic prescription
Description: GPs assigned to the intervention group attended a two days didactic educational meeting on evidence-based guidelines for diagnosis and treatment of acute respiratory tract infection.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No education on antibiotic prescription rules.
Description: GPs assigned to control group received no specific recommendations on antibiotic prescription.
Study: NCT00806143

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive transcranial stimulation (rTMS)
Description: Repetitive TMS will be administered using a MAGSTIM rapid magnetic stimulator (Magstim Company, Ltd., Whitland, U.K.) and a 70-mm figure-eight shaped coils.~In monolateral treatment in right DLPFC, three 140-second trains will be applied at 1 Hz and at 110% of RMT. There is a 30 seconds intertrain interval (total of 420 stimuli per session). In sequential treatment, the stimulation will be applied in the first to the right and then to the left dorsolateral prefrontal cortex. In right DLPFC will be applied three 140-second trains at 1 Hz and at 110% of RMT. There will be a 30 seconds intertrain interval (total of 420 stimuli per session). In left DLPFC will be applied twenty 5-second trains were applied at 10 Hz and at 100% of RMT. There will be a 25-second intertrain interval (total of 1000 stimuli per session). Patients will be treated from Monday to Friday, for a total of 15 days.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: unilateral stimulation
Description: Patients will be treated from Monday to Friday, for a total of 15 days in the same timeframe of the active group right sided low frequency stimulation
Study: NCT02809378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: newly developed 5-HT3 antagonists with long half life (48 hrs) intravenous administration prior to anesthesia induction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sevoflurane
Description: Inhalational anesthetics Halogenated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sevoflurane
Description: Inhalational anesthetics Halogenated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sevoflurane
Description: Inhalational anesthetics Halogenated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remifentanil
Description: ultra-short acting opioid anesthetics

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remifentanil
Description: ultra-short acting opioid anesthetics

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pentothal sodium
Description: intra-venous anesthetics for anesthesia induction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: intra-venous anesthetics for anesthesia induction and maintenance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: intra-venous anesthetics for anesthesia induction and maintenance
Study: NCT03204422

Intervention type: OTHER
Intervention: No intervention
Description: no any other intervention

Intervention type: OTHER
Intervention: No intervention
Description: no any other intervention
Study: NCT00711789

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Angiotensin II
Description: Angiotensin II will be given by continuous infusion for 24 hours starting at a dose of 5ng/kg/min and then titrated to a maximum dose of 15 ng/kg/min according to a blood pressure based protocol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: Saline placebo will be given by continuous infusion according to a blood-pressure base protocol. This protocol will also incorporate noradrenaline for blood pressure control (as is true in the active drug arm), such that blood pressure targets will be rapidly achieved in both arms of the study; the only difference being that in the active drug arm, at least part of the pressor effect will be provided by angiotensin II.
Study: NCT00133224

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunotherapy allogeneic GM-CSF secreting cellular vaccine
Description: Immunotherapy allogeneic GM-CSF secreting cellular vaccine

Intervention type: DRUG
Group type: OTHER
Intervention: Chemotherapy (docetaxel and prednisone)
Description: Chemotherapy (docetaxel and prednisone)
Study: NCT06086483

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.2% Injectable Solution
Description: 20 mL 0.5% ropivacaine was injected into the PENG block~20 mL 0.5% ropivacaine was injected into the Adductor Canal block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9%sodium chloride
Description: 20 mL 0.9% sodium chloride was injected into the PENG block~20 mL 0.5% sodium chloride was injected into the Adductor Canal block
Study: NCT03354624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sterile solutions of recombinant human nerve growth factor (NGF)
Description: The intramuscular injections of NGF cause muscle soreness.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sterile solutions of recombinant human nerve growth factor (NGF)
Description: The intramuscular injections of NGF cause muscle soreness.
Study: NCT02943915

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ekso GT Rehabilitation Therapy
Description: Walking Improvement for Spinal Cord Injuries with Exoskeleton

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Body Weight Supported (BWS) Treadmill Training
Description: Standard gait training using BWS PT and overground training
Study: NCT00756782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAC-101
Description: Patients will receive TAC-101 20 mg (2 x 10-mg formulated tablets) administered orally every day with approximately 8 oz. water within 1 hour following a morning meal for 14 days followed by a 7-day recovery period, repeated every 21 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive placebo (two matching tablets) at same frequency and duration of active treatment
Study: NCT02516319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICG Dye

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ICG Dye
Study: NCT02915913

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: High Intensity Interval
Description: Walking on a treadmill 4min at 80-90% peak heart rate and recovery 4 min at 65% peak heart rate until expenditure of 500 kcal

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Completing a resistance circuit (including upper and lower muscle groups) as many times as needed according to subject weight until expenditure of 500 kcal

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Plus: High Intensity Interval + Resistance Training
Description: Walking on a treadmill as intervention 1 until 50% the energy expenditure prescribed is reached, then completing a resistance circuit until 100% energy expenditure is reached

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-exercise
Description: This group will receive the usual clinical care according to the consensus recommendations of the national goals for cardiovascular health promotion and disease reduction of the American Heart Association and Colombian guidelines COLDEPORTES.
Study: NCT02343718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Study: NCT00201656

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Retention of Cerclage
Description: Retain Cerclage until clinical removal is indicated by protocol

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Removal of Cerclage
Description: Immediate removal of Cerclage following randomization

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Removal vs. Retention of Cervical Cerclage
Description: Immediate removal of cerclage following randomization vs. retention of cerclage until labor, chorioamnionitis, or fetal distress

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Removal vs. Retention of Cervical Cerclage
Description: Immediate removal of cerclage following randomization vs. retention of cerclage until labor, chorioamnionitis, or fetal distress
Study: NCT01979003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorescein
Study: NCT02924129

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Evoke Spinal Cord Stimulator (SCS) System
Description: Spinal Cord Stimulation that measures and records evoked compound action potentials (ECAPs).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evoke Spinal Cord Stimulator (SCS) System
Description: Spinal Cord Stimulation that measures and records evoked compound action potentials (ECAPs).
Study: NCT01884935

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Natalizumab
Description: As specified in the treatment arm
Study: NCT03804138

Intervention type: OTHER
Intervention: Anti-influenza and DTp pertussis vaccinations
Description: Anti-influenza and DTp pertussis vaccinations will be performed during the visit by the clinical research nurse. The vaccine has been prescribed as part of the care either by the patient's physician (pulmonologist or general practitioner).

Intervention type: OTHER
Intervention: Anti-influenza and DTp pertussis vaccinations
Description: Anti-influenza and DTp pertussis vaccinations will be performed during the visit by the clinical research nurse. The vaccine has been prescribed as part of the care either by the patient's physician (pulmonologist or general practitioner).
Study: NCT03931629

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CONVENTIONAL PHACO
Description: Cataract surgery by means of Femtosecond Laser-Assisted Cataract Surgery,

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CONVENTIONAL PHACO
Description: Cataract surgery by means of Femtosecond Laser-Assisted Cataract Surgery,
Study: NCT06282731

Intervention type: DRUG
Group type: OTHER
Intervention: Silodosin
Description: Indications:Benign prostate hyperplasia
Study: NCT03491501

Intervention type: OTHER
Intervention: Ergonomic evaluation using questionnaires
Description: Employees will be provided with questionnaires such as the 'Rapid Entire Body Assessment' and NIOSH to obtain information regarding ergonomic working situations
Study: NCT02793115

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Disclosure Letter-RISKS
Description: This disclosure letter will provide information on the physicians' financial relationships with industry, and will also provide a standardized statement regarding the potential RISKS of physicians' conflicts of interest with for-profit industry. This letter also includes a standard statement reminding the patient about the appointment and the location of the appointment.
Study: NCT00838058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CE-224,535
Description: one 250mg tablet, once in the morning in fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CE-224,535
Description: 2x250 mg tablets, once in the morning, in fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CE-224,535
Description: 4x250mg tablets, once in the morning, in fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CE-224,535
Description: 2x250mg tab, once in the morning, after being fed a high fat meal
Study: NCT01780272

Intervention type: OTHER
Group type: OTHER
Intervention: glucose clamp
Description: Each subject will complete one adaptation night visit followed by two experimental night visits, one normoglycaemic and one hypoglycaemic, in randomised order. While subjects are asleep, sleep patterns will be monitored online using polysomnographic recordings during a hypoglycaemic and a normoglycaemic clamp (using constant intravenous (i.v.) infusion of human soluble insulin (Actrapid®)). Plasma glucose will be monitored.
Study: NCT00838058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CE-224,535
Description: 4x125 mg tabs, once in the morning, in the fasted state. This arm will only occur as part of Part 2, if needed, pending results of Part 1.
Study: NCT00211042

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study. No medication will be given to the participants. Participants will receive standard-of-care treatment from their individual physicians.
Study: NCT00838058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CE-224,535
Description: 4x125 mg IR once in the morning after being fed a high fat meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CE 224,535
Description: 2x250 mg controlled release formulation 5 tabs once in the morning in the fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CE 224,535
Description: 2x250 mg controlled release formulation 5 once in the morning after being fed a high fat meal
Study: NCT01834287

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Intervention
Description: Participants in the Physical Activity intervention arm of the study receive a Spanish language, motivationally-tailored, Internet-based Physical Activity intervention that specifically addresses the Physical Activity barriers and intervention needs/preferences of Latinas.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wellness Control
Description: Participants will receive a Spanish language, Internet-based Wellness Contact control intervention addressing relevant health topics other than physical activity.
Study: NCT03958266

Intervention type: DEVICE
Intervention: MyIBD Care
Description: Novel mobile phone application
Study: NCT01984775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2894512 cream
Description: GSK2894512 is a white to off-white cream that will be applied topically in 3 different concentrations (0.5% \[5 milligram (mg)/gram (g)\], 1% \[10 mg/g\], and 2% \[20 mg/g\]).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2894512 cream
Description: GSK2894512 is a white to off-white cream that will be applied topically in 3 different concentrations (0.5% \[5 milligram (mg)/gram (g)\], 1% \[10 mg/g\], and 2% \[20 mg/g\]).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2894512 cream
Description: GSK2894512 is a white to off-white cream that will be applied topically in 3 different concentrations (0.5% \[5 milligram (mg)/gram (g)\], 1% \[10 mg/g\], and 2% \[20 mg/g\]).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle cream
Description: Vehicle cream does not contain any active pharmaceutical ingredient.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Positive control
Description: Positive control contains sodium lauryl sulfate solution 0.1% (1 mg/g).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Negative control
Description: Negative control contains petrolatum.
Study: NCT03592147

Intervention type: OTHER
Group type: OTHER
Intervention: Guided Imagery Relaxation Tape
Description: The meditation is approximately 7 minutes in duration.

Intervention type: OTHER
Group type: OTHER
Intervention: Music Listening
Description: Participants have the option of selecting one of the following music categories: New age, classical, and oriental. The songs were selected based on criteria established in a previous study to induce relaxation. All songs were also modified in length to be approximately 7 minutes in duration.

Intervention type: OTHER
Group type: OTHER
Intervention: Relaxation Lighting
Description: The participants were asked to select either orange or blue lighting settings using the Philips Hue lighting. The intensity of the light will be fixed to control for that measure. They were asked to sit for approximately 7 minutes in duration.

Intervention type: OTHER
Group type: OTHER
Intervention: Meditation and Relaxation Light
Description: The guided imagery meditation and relaxation lighting were combined.

Intervention type: OTHER
Group type: OTHER
Intervention: Music and Relaxation Light
Description: The music and relaxation lighting were combined.

Intervention type: OTHER
Group type: OTHER
Intervention: Control/Silence
Description: The participants were asked to relax for a duration of 7 minutes, with no explicit advice given. Lighting was adjusted to a specific intensity and colour (basic yellow light) as was used in the music and guided imagery interventions.
Study: NCT02793115

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Disclosure Letter-BENEFITS
Description: This disclosure letter will provide information on the physicians' financial relationships with industry, and will also provide a standardized statement regarding the potential BENEFITS of physicians' conflicts of interest with for-profit industry. This letter also includes a standard statement reminding the patient about the appointment and the location of the appointment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Disclosure Letter-RISKS AND BENEFITS
Description: This disclosure letter will provide information on the physicians' financial relationships with industry, and will also provide a standardized statement regarding the potential RISKS AND BENEFITS of physicians' conflicts of interest with for-profit industry. This letter also includes a standard statement reminding the patient about the appointment and the location of the appointment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Disclosure Letter-NO RISKS OR BENEFITS
Description: This letter includes a standard statement reminding the patient about the appointment and the location of the appointment.and DOES NOT provide any information on the physicians' financial relationships with industry nor information regarding the potential risks and benefits of physicians' conflicts of interest with for-profit industry.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Letter-APPOINTMENT REMINDER
Description: This letter only includes a standard statement reminding the patient about the appointment and the location of the appointment.
Study: NCT00670098

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Description: patients receive either gastric bypass or lap-band

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle intervention (behavioral weight loss)
Description: participants attend biweekly weight loss counseling group sessions
Study: NCT04873609

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient portal message
Description: Direct-to-patient message via the electronic patient portal (MyHealth) with HCV antibody lab order directed to their preferred laboratory

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient portal message
Description: Direct-to-patient message via the electronic patient portal (MyHealth) with HCV antibody lab order directed to their preferred laboratory
Study: NCT01455064

Intervention type: DEVICE
Intervention: FreeStyle Navigator II Continuous Glucose Monitoring System
Description: This is not an interventional study. Subjects must maintain their own diabetes treatment regimen throughout the study duration
Study: NCT03853746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Patient will be treated with two courses of ocrelizumab (Ocrevus) for one year and then will stop the medication and will be monitored for the return of the disease activity. Those who experience return of the disease activity can go back on the medication.
Study: NCT01233245

Intervention type: DRUG
Intervention: Interferon beta-1b (Betaseron, BAY86-5046)
Description: 250 µg, sub-cutaneously, on alternate days
Study: NCT01206647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin and Saxagliptin
Description: Metformin 500mg/daily titrated to 2000mg/d in 4 Weeks (continued for 20 weeks) Saxagliptin 5 mg daily over complete trial
Study: NCT01318447

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CyberKnife SBRT
Description: Dose is 45 Gy (15 Gy in 3 fractions) and delivered over 5 to 10 days.